Michael Halstead - 01 Mar 2025 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
President
Signature
/s/ John P. Condon, Attorney-in-fact
Issuer symbol
ITCI
Transactions as of
01 Mar 2025
Net transactions value
-$802,660
Form type
4
Filing time
04 Mar 2025, 18:01:07 UTC
Previous filing
04 Feb 2025
Next filing
10 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise +12,239 +230% 17,565 01 Mar 2025 Direct F1
transaction ITCI Common Stock Tax liability $802,660 -6,261 -36% $128.20 11,304 01 Mar 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Restricted Stock Units Options Exercise $0 -12,239 -33% $0.000000 24,478 01 Mar 2025 Common Stock 12,239 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units and does not represent a sale by the reporting person.
F3 Each restricted stock unit represents a contingent right to receive one share of common stock.
F4 On March 1, 2024, the reporting person was granted 36,717 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.